(Q39222901)

10 September 2017

title

Antitumor activities of PSMA×CD3 diabodies by redirected T-cell lysis of prostate cancer cells (English)

1 reference

10 September 2017

1 reference

5

Gina J Fiala

0 references

Wolfgang Schamel

6

object named as

Wolfgang Wa Schamel

0 references

author name string

Volker Baum

1

1 reference

10 September 2017

Patrick Bühler

2

1 reference

10 September 2017

Dorothee Gierschner

3

1 reference

10 September 2017

Dieter Herchenbach

4

1 reference

10 September 2017

Gina J Fiala

5

1 reference

10 September 2017

Wolfgang Wa Schamel

6

1 reference

10 September 2017

Philipp Wolf

7

1 reference

10 September 2017

Ursula Elsässer-Beile

8

1 reference

10 September 2017

publication date

1 January 2013

1 reference

10 September 2017

1 reference

10 September 2017

volume

5

1 reference

10 September 2017

issue

1

1 reference

10 September 2017

page(s)

27-38

1 reference

10 September 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Targeted therapies for prostate cancer against the prostate specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Bispecific antibodies for cancer immunotherapy: Current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Recombinant bispecific antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Analysis of molecular masses and oligomeric states of protein complexes by blue native electrophoresis and isolation of membrane protein complexes by two-dimensional native electrophoresis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Blue native polyacrylamide gel electrophoresis (BN-PAGE) for the identification and analysis of multiprotein complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Target-dependent T-cell activation by coligation with a PSMA x CD3 diabody induces lysis of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

The human immune system in hu-PBL-SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Humanized mice in translational biomedical research

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.12.136

21 January 2018

Identifiers

DOI

10.2217/IMT.12.136

1 reference

release_wcmgl3psdbdcpdoiledv57g37y

10 September 2017

Fatcat ID

0 references

1 reference